accountDURECT Corporation (Nasdaq: DRRX) announced that its licensee, King Pharmaceuticals (NYSE: KG), has begun a Phase IIb clinical trial to evaluate...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to DURECT Corporation Announces Commencement Of Phase IIb ELADUR(TM
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account